Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery

Kaleeckal G. Harikumar, Denise Wootten, Delia I. Pinon, Cassandra Koole, Alicja M. Ball, Sebastian G B Furness, Bim Graham, Maoqing Dong, Arthur Christopoulos, Laurence J Miller, Patrick M. Sexton

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) is a family B G protein-coupled receptor and an important drug target for the treatment of type II diabetes, with activation of pancreatic GLP-1Rs eliciting glucose-dependent insulin secretion. Currently, approved therapeutics acting at this receptor are peptide based, and there is substantial interest in small molecule modulators for the GLP-1R. Using a variety of resonance energy transfer techniques, we demonstrate that the GLP-1R forms homodimers and that transmembrane helix 4 (TM4) provides the primary dimerization interface. We showthat disruption of dimerization using a TM4 peptide, a minigene construct encoding TM4, or by mutation of TM4, eliminates G protein-dependent high-affinity binding to GLP-1(7-36)NH2 but has selective effects on receptor signaling. There was <10-fold decrease in potency in cAMP accumulation or ERK1/2 phosphorylation assays but marked loss of intracellular calcium mobilization by peptide agonists. In contrast, there was near-complete abrogation of the cAMP response to an allosteric agonist, compound 2, but preservation of ERK phosphorylation. Collectively, this indicates that GLP-1R dimerization is important for control of signal bias. Furthermore,we reveal that two small molecule ligands are unaltered in their ability to allosterically modulate signaling from peptide ligands, demonstrating that these modulators act in cis within a single receptor protomer, and this has important implications for small molecule drug design.

Original languageEnglish (US)
Pages (from-to)18607-18612
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number45
DOIs
StatePublished - Nov 6 2012

Fingerprint

Dimerization
Peptides
Phosphorylation
Ligands
Glucagon-Like Peptide 1
Peptide Receptors
Drug Design
Energy Transfer
Protein Subunits
G-Protein-Coupled Receptors
GTP-Binding Proteins
Type 2 Diabetes Mellitus
Insulin
Calcium
Glucose
Mutation
Glucagon-Like Peptide-1 Receptor
Pharmaceutical Preparations
Therapeutics

Keywords

  • Allosteric modulation
  • Biased signaling
  • Family B GPCRs
  • G protein-coupled receptors

ASJC Scopus subject areas

  • General

Cite this

Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. / Harikumar, Kaleeckal G.; Wootten, Denise; Pinon, Delia I.; Koole, Cassandra; Ball, Alicja M.; Furness, Sebastian G B; Graham, Bim; Dong, Maoqing; Christopoulos, Arthur; Miller, Laurence J; Sexton, Patrick M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 45, 06.11.2012, p. 18607-18612.

Research output: Contribution to journalArticle

Harikumar, Kaleeckal G. ; Wootten, Denise ; Pinon, Delia I. ; Koole, Cassandra ; Ball, Alicja M. ; Furness, Sebastian G B ; Graham, Bim ; Dong, Maoqing ; Christopoulos, Arthur ; Miller, Laurence J ; Sexton, Patrick M. / Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. In: Proceedings of the National Academy of Sciences of the United States of America. 2012 ; Vol. 109, No. 45. pp. 18607-18612.
@article{3fc7270dbffe4524af262864e3a0a46b,
title = "Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery",
abstract = "The glucagon-like peptide-1 receptor (GLP-1R) is a family B G protein-coupled receptor and an important drug target for the treatment of type II diabetes, with activation of pancreatic GLP-1Rs eliciting glucose-dependent insulin secretion. Currently, approved therapeutics acting at this receptor are peptide based, and there is substantial interest in small molecule modulators for the GLP-1R. Using a variety of resonance energy transfer techniques, we demonstrate that the GLP-1R forms homodimers and that transmembrane helix 4 (TM4) provides the primary dimerization interface. We showthat disruption of dimerization using a TM4 peptide, a minigene construct encoding TM4, or by mutation of TM4, eliminates G protein-dependent high-affinity binding to GLP-1(7-36)NH2 but has selective effects on receptor signaling. There was <10-fold decrease in potency in cAMP accumulation or ERK1/2 phosphorylation assays but marked loss of intracellular calcium mobilization by peptide agonists. In contrast, there was near-complete abrogation of the cAMP response to an allosteric agonist, compound 2, but preservation of ERK phosphorylation. Collectively, this indicates that GLP-1R dimerization is important for control of signal bias. Furthermore,we reveal that two small molecule ligands are unaltered in their ability to allosterically modulate signaling from peptide ligands, demonstrating that these modulators act in cis within a single receptor protomer, and this has important implications for small molecule drug design.",
keywords = "Allosteric modulation, Biased signaling, Family B GPCRs, G protein-coupled receptors",
author = "Harikumar, {Kaleeckal G.} and Denise Wootten and Pinon, {Delia I.} and Cassandra Koole and Ball, {Alicja M.} and Furness, {Sebastian G B} and Bim Graham and Maoqing Dong and Arthur Christopoulos and Miller, {Laurence J} and Sexton, {Patrick M.}",
year = "2012",
month = "11",
day = "6",
doi = "10.1073/pnas.1205227109",
language = "English (US)",
volume = "109",
pages = "18607--18612",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "45",

}

TY - JOUR

T1 - Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery

AU - Harikumar, Kaleeckal G.

AU - Wootten, Denise

AU - Pinon, Delia I.

AU - Koole, Cassandra

AU - Ball, Alicja M.

AU - Furness, Sebastian G B

AU - Graham, Bim

AU - Dong, Maoqing

AU - Christopoulos, Arthur

AU - Miller, Laurence J

AU - Sexton, Patrick M.

PY - 2012/11/6

Y1 - 2012/11/6

N2 - The glucagon-like peptide-1 receptor (GLP-1R) is a family B G protein-coupled receptor and an important drug target for the treatment of type II diabetes, with activation of pancreatic GLP-1Rs eliciting glucose-dependent insulin secretion. Currently, approved therapeutics acting at this receptor are peptide based, and there is substantial interest in small molecule modulators for the GLP-1R. Using a variety of resonance energy transfer techniques, we demonstrate that the GLP-1R forms homodimers and that transmembrane helix 4 (TM4) provides the primary dimerization interface. We showthat disruption of dimerization using a TM4 peptide, a minigene construct encoding TM4, or by mutation of TM4, eliminates G protein-dependent high-affinity binding to GLP-1(7-36)NH2 but has selective effects on receptor signaling. There was <10-fold decrease in potency in cAMP accumulation or ERK1/2 phosphorylation assays but marked loss of intracellular calcium mobilization by peptide agonists. In contrast, there was near-complete abrogation of the cAMP response to an allosteric agonist, compound 2, but preservation of ERK phosphorylation. Collectively, this indicates that GLP-1R dimerization is important for control of signal bias. Furthermore,we reveal that two small molecule ligands are unaltered in their ability to allosterically modulate signaling from peptide ligands, demonstrating that these modulators act in cis within a single receptor protomer, and this has important implications for small molecule drug design.

AB - The glucagon-like peptide-1 receptor (GLP-1R) is a family B G protein-coupled receptor and an important drug target for the treatment of type II diabetes, with activation of pancreatic GLP-1Rs eliciting glucose-dependent insulin secretion. Currently, approved therapeutics acting at this receptor are peptide based, and there is substantial interest in small molecule modulators for the GLP-1R. Using a variety of resonance energy transfer techniques, we demonstrate that the GLP-1R forms homodimers and that transmembrane helix 4 (TM4) provides the primary dimerization interface. We showthat disruption of dimerization using a TM4 peptide, a minigene construct encoding TM4, or by mutation of TM4, eliminates G protein-dependent high-affinity binding to GLP-1(7-36)NH2 but has selective effects on receptor signaling. There was <10-fold decrease in potency in cAMP accumulation or ERK1/2 phosphorylation assays but marked loss of intracellular calcium mobilization by peptide agonists. In contrast, there was near-complete abrogation of the cAMP response to an allosteric agonist, compound 2, but preservation of ERK phosphorylation. Collectively, this indicates that GLP-1R dimerization is important for control of signal bias. Furthermore,we reveal that two small molecule ligands are unaltered in their ability to allosterically modulate signaling from peptide ligands, demonstrating that these modulators act in cis within a single receptor protomer, and this has important implications for small molecule drug design.

KW - Allosteric modulation

KW - Biased signaling

KW - Family B GPCRs

KW - G protein-coupled receptors

UR - http://www.scopus.com/inward/record.url?scp=84868585481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868585481&partnerID=8YFLogxK

U2 - 10.1073/pnas.1205227109

DO - 10.1073/pnas.1205227109

M3 - Article

C2 - 23091034

AN - SCOPUS:84868585481

VL - 109

SP - 18607

EP - 18612

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 45

ER -